Company profile: Protagenic Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology solutions developing naturally occurring human brain hormones to treat anxiety- and depression-based mood disorders. Offers PT00114, a synthetic analog of the neuropeptide TCAP that regulates stress response for depression, PTSD, anxiety, and addiction, and the TCAP R&D platform to address neuropsychiatric and neurodegenerative diseases at the cellular level in the brain.
Products and services
- PT00114: A neuropeptide-derived synthetic analog of TCAP engineered to modulate stress-response pathways and treat depression, PTSD, anxiety, and addiction across neuropsychiatric indications
- TCAP Platform: A cellular-level R&D platform that architects TCAP-based products to mediate brain stress-response signaling and explore treatments for diverse neuropsychiatric and neurodegenerative diseases
- Human Brain Hormone Discovery & Development: A naturally occurring human brain hormone program that develops therapeutics targeting anxiety- and depression-based mood disorders through focused discovery and development initiatives
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Protagenic Therapeutics
Nalu Medical
HQ: United States
Website
- Description: Provider of innovative medical technology solutions for patients with chronic neuropathic pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nalu Medical company profile →
Tetra Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology therapeutics for cognitive and memory deficits. Develops BPN14770, a selective PDE4D allosteric inhibitor for Fragile X syndrome and Alzheimer’s disease; a PDE4B inhibitor to reduce inflammation and improve cognitive function in traumatic brain injury and progressive multiple sclerosis; and conducts ongoing clinical trials for memory loss treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tetra Therapeutics company profile →
Neurocare
HQ: Germany
Website
- Description: Provider of a digital therapy platform integrating technology, training, software, and services to personalize mental health therapy after detailed assessment, plus devices for neuromodulation and monitoring, including TMS systems, neurofeedback (with optional biofeedback), EEG & QEEG systems, tDCS stimulators, and actigraphy devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurocare company profile →
iPierian
HQ: United States
Website
- Description: Provider of a drug discovery platform leveraging induced pluripotent stem cells to discover and develop therapies for neurodegenerative diseases, including SMA, ALS, and Parkinson's, addressing other major unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iPierian company profile →
Corium
HQ: United States
Website
- Description: Provider of biopharmaceutical treatments for central nervous system conditions; a commercial-stage company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corium company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Protagenic Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Protagenic Therapeutics
2.2 - Growth funds investing in similar companies to Protagenic Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Protagenic Therapeutics
4.2 - Public trading comparable groups for Protagenic Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →